TV News LIES

Sunday, Jan 22nd

Last update05:20:13 AM GMT

You are here News Health Study outcome won't sway company on eye drug

Study outcome won't sway company on eye drug

E-mail Print PDF

What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?

In the case of Genentech Inc., nothing.

The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance _ or cooperate with _ a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.

More...


Most Recent Related Stories...


Study linking Roundup to serious disease fuels debate

Roundup health hazardUK scientists say they have conducted an unprecedented, long-term study showing a link between Roundup -...

18 Million People Could Lose Insurance In First Year After Partial Obamacare Repeal

18 million people could lose health insuranceA partial repeal of Obamacare could leave 18 million people who have insurance today with no...

Mark Gastineau: I have dementia, Alzheimer’s and Parkinson’s

Mark GastineauMark Gastineau, the flamboyant former Jets defensive end and centerpiece of their infamous Sack Exchange, always...

Obamacare Rallies Around the Country

Obamacare ralliesSupporters of the Affordable Care Act gathered to protest the health care law’s repeal in rallies...
 
America's # 1 Enemy
Tee Shirt
& Help Support TvNewsLIES.org!
TVNL Tee Shirt
 
TVNL TOTE BAG
Conserve our Planet
& Help Support TvNewsLIES.org!
 
Get your 9/11 & Media
Deception Dollars
& Help Support TvNewsLIES.org!
 
The Loaded Deck
The First & the Best!
The Media & Bush Admin Exposed!